TP53 and non-small cell lung carcinoma: In the NSCLC discovery cohort (n = 349), the ORR in TP53_MUT patients was almost twice that in TP53_WT patients (29.7% vs. 19.1%, OR = 1.79, 95% CI = 1.08–2.98, p = 0.025) (Supplementary Figure S1A).